Infinity Pharma Appoints Samuel Agresta Chief Medical Officer

Samuel Agresta has been appointed chief medical officer of Cambridge, MA-based Infinity Pharmaceuticals (NASDAQ: [[ticker:INFI]]). Agresta comes to Infinity from Agios Pharmaceuticals (NASDAQ: [[ticker:AGIO]]), where he was vice president and head of clinical development. Before Agios, Agresta held posts at Merrimack Pharmaceuticals (NASDAQ: [[ticker:MACK]]) and Genentech. Following a corporate restructuring last year, Infinity turned its focus toward IPI-549, a cancer drug for solid tumors that is in early-stage clinical testing.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.